Illumina (ILMN) announced that reimbursement has been granted for its FDA-approved in vitro diagnostic TruSight Oncology, or TSO, Comprehensive test. TSO Comprehensive gives clinicians the ability to simultaneously assess hundreds of genes-including relevant cancer biomarkers-to inform treatment decisions. The reimbursement decision from the Centers for Medicare and Medicaid Services will expand access to comprehensive genomic profiling and the growing role of personalized genomics in oncology care. TSO Comprehensive enables laboratories of all sizes to deliver FDA-approved, clinically valuable genomic insights that are easy to access and implement.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $155 from $135 at Stifel
- Illumina: Rich Valuation Amid Mounting Competitive and Execution Risks Supports Sell Rating
- Cathie Wood Doubles Down on High-Potential Biotech Plays
- Midday Fly By: JPMorgan reports mixed Q4, L3Harris to form new missile company
- Illumina introduces Billion Cell Atlas